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Abstract
Purpose The tumour’s ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aber-
rant E-Cadherin expression has been linked to invasiveness and poor prognosis.
Method We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue from 125 female breast 
cancer patients. Staining intensities were analysed using the immunoreactive score (IRS). We investigated E-Cadherin 
expression and its associations with clinicopathological parameters (age, tumour size, lymph node status, grade, hormone 
receptors, Her2 Status) as well as with recurrence and survival.
Results Increased, rather than aberrant E-Cadherin expression was found and was associated with poor outcome (p = 0.046). 
Our data show an association between elevated E-Cadherin in primary tumour tissue and an unfavourable negative prognosis 
in patients.
Conclusion This association was somehow unexpected as loss of E-Cadherin has long been regarded as a prerequisite for 
development of invasiveness and metastases. Our findings support the notion that E-Cadherin promotes, rather than sup-
presses, development of metastasis and invasiveness.
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Introduction
With a worldwide incidence of 1.67 million patients per 
year, breast cancer is the most common cancer and with 
about half a million deaths per year, the leading cause of 
mortality in women worldwide [1]. Even though the inci-
dence of breast cancer remains very high, the mortality rate 
has declined over the past 20 years [2]. This is mainly due 
to improved treatment options, which have developed from 
conventional locoregional to systemic targeted anti-tumour 
therapies. Depending on tumour subtype, surgery, radio-
therapy, and systemic treatments such as endocrine therapy, 
targeted treatment, and chemotherapy are key treatment 
options [3].
The ability of cancer cells to migrate from the primary 
tumour site and form metastases is one of the hallmarks of 
cancer and the leading cause of death in cancer patients [4]. 
One postulated explanation for this ability is the assump-
tion that single tumour cells emigrate individually from the 
primary tumour site mediated by processes called epithelial-
mesenchymal transition (EMT). Individual cell movement 
is one of the best-studied cell movement mechanism [5].
During the cellular process of EMT epithelial cells lose 
their epithelial features and acquire mesenchymal char-
acteristics [6]. EMT has been associated with loss of the 
cell-to-cell adhesion molecule E-Cadherin and gain of the 
mesenchymal marker Vimentin [7]. It has recently been 
postulated that EMT might not simply be a binary process, 
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as previously assumed, but a more complex process in 
which cells go through different developmental transition 
states, which are defined by various types of epithelial and 
mesenchymal markers [8].
E-Cadherin, a member of the Cadherin-superfamily, is 
a calcium-dependent transmembrane glycoprotein, first 
described in 1977 by Takeichi [9]. A type-1-cadherine, 
E-Cadherin has multiple roles in physiological as well 
as pathological processes of cell migration and invasion, 
such as embryonic development [10], tissue morphogen-
esis [11] and cell–cell adhesion between neighbouring 
epithelial cells [12]. The role of E-Cadherin in cancer 
progression is established and well documented [13–16], 
represented by repression of E-Cadherin expression at the 
primary tumour site [17, 18]. E-Cadherin has been clas-
sified as a tumour suppressor and diminished E-Cadherin 
expression in epithelial cancer cells has been related to the 
process of EMT in multiple carcinomas, including breast 
cancer [19, 20] and to the acquisition of chemoresistance 
[21, 22].
The purpose of this study was to evaluate the relevance 
of E-Cadherin expression in tumour tissue at different 
stages, in the punch biopsies before any treatment and at 
the time of surgery, in patients with breast cancer. To our 
knowledge, little data exists concerning E-Cadherin as a 
marker involved in cancer development for prediction of 
outcome in patients. Therefore, we evaluated E-Cadherin 
expression and its associations with clinicopathological 
parameters as well as patient outcome.
Materials and methods
Patients
In this study, we included patients with primary breast can-
cer diagnosis, i.e. non-metastatic disease, who were diag-
nosed and treated between 2005 and 2015 at the Breast 
Center, Department of Gynaecology and Obstetrics, Lud-
wig-Maximilians-University of Munich, Germany. Patients 
with primary metastatic disease were excluded as well as 
patients with pathological complete response (pCR) after 
neoadjuvant chemotherapy since we aimed to analyse and 
compare tumour tissue in the punch biopsy and at time of 
surgery. Data from 1027 patients with primary breast cancer 
that had been registered at the breast center of the LMU 
University Hospital between 2005 and 2015 had been con-
sidered for inclusion in this study. Of these, 125 patients 
with sufficient tumour tissue still available for analysis who 
met these criteria were identified. For the inclusion and 
exclusion process (see Fig. 1). Of the 125 selected breast 
cancer patients 95 patients had either a punch biopsy tissue 
(N = 62) at time of initial diagnosis or a surgical specimen 
(N = 78) or both (N = 45). Ethical compliance of the study 
was approved by the institutional review board of Munich, 
Germany (number: 17-819).
Demographic data including age at diagnosis, tumour 
grade, TNM Status, Hormone receptor status (progesterone 
and estrogen receptor status) and Her2 Status were retrieved 
from the Munich Cancer Registry or the Institute of Pathol-














Fig. 1  Flowchart demonstrating data from 1027 patients with primary 
breast cancer that had been registered at the breast center of the LMU 
University Hospital between 2005 and 2015 and had been consid-
ered for inclusion in this study. From these 1027 patients, we had to 
exclude 98 patients because of either primary metastasis or second-
ary cancer diseases. From the remaining 929 breast cancer patients, 
425 patients with pathological complete response (pCR) had been 
excluded. Further on, because of unfinished treatment due to death, 
loss to follow-up or continued external treatment we had to exclude 
187 more patients, leaving 317 for further analysis
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were contacted via phone to collect information about pre-
sent progression- and survival information. Recurrence sta-
tus could be assessed in 104 out of 125 patients. Of these 
104 patients, 9 (8.7%) had experienced a recurrence event, 
whereas 95 (91.3%) were still recurrence-free at time of 
analysis. The median follow-up period in years was 7.86 
(see Table 1).
Immunohistochemistry
Punch biopsy as well as surgical tissue was used for anal-
ysis. Tissue specimens were formalin-fixed and paraffin 
embedded before sectioned into 10 µm slices. Expres-
sion of E-Cadherin was assessed by immunohistochem-
istry. E-Cadherin staining was performed as described 
































 Primary surgery 57 45.6
 Neoadjuvant chemotherapy 68 54.4
 Adjuvant endocrine therapy 24 19.2
 (intra-/postsurgical radiation) 93 74.4
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previously [23]. Primary anti-E-Cadherin antibody (mon-
oclonal mouse IgG1, Abcam, Cambridge, UK), was used 
for tissue slide staining. Detection was performed via 
polymer-method (ZytoChem Plus HRP Polymer System 
(Mouse/Rabbit); Zytomed Systems Berlin, Germany; Nr. 
POLHRP-100) and chromogen diaminobenzidine (Dako, 
Hamburg, Germany) (See Fig. 2 for example stainings).
Colon tissue was stained simultaneously and used as 
a positive control. Expression of E-Cadherin was then 
assessed by the semi-quantitative immunoreactivity score 
(IRS) using a Leitz (Wetzlar, Germany) microscope. 
The IRS is the product of the intensity of the staining 
(0 = no staining, 1 = weak staining, 2 = moderate stain-
ing, 3 = strong staining) multiplied by the percentage of 
positive cells (0 = no staining, 1 =  < 10% positive cells, 
2 = 11–50% positive cells, 3 = 51–80%, 4 =  > 81% positive 
cells). This multiplication has a minimum of 0 and a maxi-
mum of 12. Samples were then categorized as E-Cadherin 
positive and E-Cadherin negative, according to their IRS: 
Samples with an IRS score of 1 or higher were counted 
as E-Cadherin positive, whereas samples with scores of 0 
were categorized as E-Cadherin negative. Mean ranks of 
the IRS scores were calculated using SPSS. For further 
detail, see section “statistical analysis”. We then compared 
E-Cadherin expression in samples from punch biopsies 
and surgical tissue samples. E-Cadherin expression was 
then correlated with clinicopathological parameters, pro-
gression-free and overall survival.
Estrogen and progesterone receptor status was catego-
rized as positive when the percentage of positive tumour 
cells stained for estrogen and progesterone was at least 
1%. The Her2 Status was defined as amplified with a FISH 
to ratio of higher than 2.2 [24] or overexpressed with an 
immunohistochemistry score of 3 + (membrane staining of 
30% of tumour cells) [25].
Statistical analyses
The statistical analysis was performed using the IBM SPSS 
software version 25. P values ≤ 0.05 were considered statisti-
cally significant. Chi-squared tests were used to determine 
independence between nominal data. For non-parametric 
data Kruskal–Wallis tests and Mann–Whitney U tests 
were used to assess relationships among clinicopathologi-
cal parameters, antibody expression and type of treatment. 
Progression-free survival and overall survival curves were 
plotted using the Kaplan–Meier method. Since the data were 
not normally distributed we used the Kruskal–Wallis test to 
test for differences between several independent groups. This 
test is based on ranked data. IRS scores were ordered from 
lowest to highest; the lowest score was assigned a rank of 1, 
the next highest score was assigned a rank of 2 and so on. 
Ranks for each group are then ranked and the mean rank cal-
culated via SPSS. The sum of ranks has been calculated for 
each group, square the sum of ranks and divide this value by 
the sample size for that group. Test statistics were compared 
between the two groups.
Results
Patients’ characteristics
Our collective consisted of 125 primary breast cancer 
patients. Patients have been collected retrospectively. All 
therapies have been chosen clinically and this retrospective 
study did not interfere with treatment choice. Mean patient 
age was 54.4 years (28–81 years). 88.7% of all patients had 
a carcinoma of no special type (NST). HER2 showed to be 
amplified in 15.7% of patients. 49.2% of patients had no 
lymph node metastasis (N0), in 50.8% one or more lymph 
nodes were involved (N1 or higher). Approximately half of 
the patients (50.4%) had a G2 tumour. Type of treatment 
Fig. 2  E-Cadherin staining in 
breast cancer. E-Cadherin IRS 
was scored with 12 in picture 1 
(high intensity, ≥ 80% stained 
cells), 25 × magnified (top) 
and 10 × magnified (bottom). 
Picture 2 demonstrating an 
E-Cadherin IRS of 4 (low 
intensity, ≥ 80% stained cells), 
25 × magnified (top), 10 × mag-
nified (bottom). Picture 3 
and 4 showing positive and 
negative controls (colon tissue), 
25 × magnified (top), 10 × mag-
nified (bottom)
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was almost equally distributed between the patients: Out of 
the 125 selected patients, 57 (45.6%) had received primary 
surgery (see Table 1).
No difference of E‑Cadherin expression 
between punch biopsy and surgical specimen
We compared E-Cadherin expression in tumour tissue of 
punch biopsies and surgical samples. We initially compared 
the mean ranks of E-Cadherin IRS of all core biopsies and 
surgical specimen. No significant differences in E-Cadherin 
expression were found. This remained the case, when we 
compared the paired samples (45 pairs of tumour tissue from 
core biopsies and surgical specimen), no significant differ-
ences were found (see Fig. 2).
Associations between nodal status (pN) 
and expression of E‑Cadherin
Information about the nodal status was obtained in 59 out of 
62 patients with available core biopsies. We used the infor-
mation of nodal status at the time of primary diagnosis, prior 
to any treatment. Of these, 34 patients showed no nodal 
involvement (N0), whereas 25 patients had a positive nodal 
status (N1 or higher). Tumour tissue from patients with 
a positive nodal status showed a significantly (p = 0.034) 
higher E-cadherin IRS (median rank: 35.42) than tissue from 
patients with a negative nodal status (median rank: 26.01). 
When looked at the nodal status as the dependent variable, 
we found that amongst N0 patients (n = 34), tumour tissue 
of 3 (8.8%) patients showed a negative E-Cadherin expres-
sion (IRS < 1), whereas tumour tissue of 31 (91.2%) patients 
showed a positive E-Cadherin expression with IRS higher 
than one. As for patients (with N1 or higher status (n = 25), 
only tumour tissue of one (4%) patient was found to have a 
negative E-Cadherin expression (IRS < 2), as compared to 
24 (96%) patients with a positive E-Cadherin expression in 
their tumour tissue.
Association between hormone receptor status 
and E‑Cadherin expression
Hormone receptor status could be obtained in a total of 122 
patients. Of these 122 tumours, 89 were estrogen recep-
tor positive and 33 estrogen receptor negative, whereas 
76 were progesterone receptor positive and 46 were pro-
gesterone receptor negative (see Table 1). A highly signifi-
cant (p = 0.006) association of high E-Cadherin expression 
(median rank: 40.18) and negative estrogen receptor status 
was observed. In addition, high E-Cadherin expression 
(median rank: 36.77) also correlated significantly (p = 0.021) 
with negative progesterone receptor status.
High E‑Cadherin expression in punch biopsies 
is associated with more frequent recurrence events
Patients with tumour tissue with E-Cadherin IR scores 1 
or higher in the punch biopsy had more recurrence events. 
This correlation was found to be statistically significant 
(p = 0.046). The strength of this association was even 
stronger when selectively analysing punch biopsy tissue with 
high E-Cadherin IRS (IRS > 7).
Positive Her2 Status combined with positive 
E‑Cadherin IRS is associated with shorter time 
to recurrence
Information about E-cadherin IRS of the punch biopsy tis-
sues samples, Her2 Status and follow-up data concerning 
recurrence status and recurrence-free survival time was 
available in a total of 93 patients. Of these 93 patients, 
86 remained recurrence-free during our follow-up time, 
whereas six patients suffered from a recurrence event. Our 
data showed a significant difference (p = 0.01) between 
patients with Her2 positive status and IRS higher than one 
compared to patients who had a negative Her2 Status and 
negative E-cadherin IRS when looked at recurrence-free 
survival time. 50% of all patients, with tissue that was Her2 
status positive and E-Cadherin IRS > 1, suffered from a 
recurrence event within the first year after treatment with 
neoadjuvant chemotherapy. In comparison, the median time 
to recurrence for patients with negative Her2 Status and 
negative E-Cadherin immunoreactive scores was 7 years. 
Treatment did not differ between both groups (see Table 2).
Influence of age on E‑Cadherin expression
When we selectively analysed the 45 paired samples of 
punch biopsies and surgical samples, we found a correla-
tion between age at diagnosis and E-Cadherin expression. 
Of the selected 45 paired samples, 33 patients were 50 years 
or older, whereas 12 patients were younger than 50 years. 
We could observe the trend that tumour tissue of patients 
older than 50 years had higher E-Cadherin expression in 
the surgical specimen. This observation was independent 
of tumour biology or treatment received. Tumour tissue of 
Table 2  Comparison of median time to recurrence dependent on 
Her2 Status and E-Cadherin expression
Her2 Status negative 
and E-Cadherin IRS 
negative
Her2 Status positive 
and E-Cadherin IRS 
positive
Median time to recur-
rence (in years)
1 7,3
 Archives of Gynecology and Obstetrics
1 3
patients younger than 50 years showed a higher E-Cadherin 
expression in the punch biopsies.
Discussion
In this study, we aimed to analyse E-Cadherin expression 
in tumour tissues of patients with breast cancer at different 
time points and to assess whether this E-Cadherin expres-
sion showed a correlation to currently established prognostic 
variables. Whereas we could not observe a statistically sig-
nificant difference in E-Cadherin expression between punch 
biopsies and surgical specimens, our data demonstrated a 
correlation between E-Cadherin expression and hormone 
receptor status as well as nodal status and clinical outcome.
It has been shown that breast cancer patients with tumours 
that express hormone receptors have a reduced mortality 
[26]. About 65% of breast carcinomas express estrogen 
receptors, and these cases are usually associated with a bet-
ter prognosis [27]. A relationship between the expression of 
E-Cadherin in tumour tissue and hormone receptor expres-
sion has been noted in several studies previously [28–31]. 
However, results of these studies vary. Some studies have 
demonstrated that lower E-Cadherin expression is associated 
with estrogen receptor negative breast carcinomas, whereas 
other studies have failed to confirm these findings. Our data 
demonstrated a strong correlation between a negative hor-
mone receptor status and elevated E-Cadherin expression.
Similarly, reduced E-Cadherin expression has been shown 
to correlate with positive nodal status [32–34]. Our results 
demonstrated a strong relationship between elevated expres-
sion of E-Cadherin and development of nodal metastases. In 
addition, we observed that patients with tumours that show a 
higher E-Cadherin expression have a shorter time to recur-
rence when compared to patients with tumours with negative 
E-Cadherin expression. Although several studies have shown 
a correlation between E-Cadherin and negative prognostic 
factors such as nodal status and hormone receptor status, 
our results showing higher expression levels in these tumour 
tissues were somehow unexpected, as typically reduced 
E-Cadherin expression has been linked to invasiveness and 
poor prognosis [19, 20, 29–31, 35–41]. Nevertheless, these 
findings are also in line with results of a recent study and 
the notion that E-Cadherin promotes, rather than suppresses, 
development of metastasis. E-Cadherin expression levels 
were not only reported to be elevated, but also shown to be 
significantly associated with poor clinical outcome. Instead 
of suppressing metastasis, expression of E-Cadherin was 
found to function as a promotor of metastasis [8]. Other 
studies have also demonstrated a more complex role for 
E-Cadherin, as it has been shown that expression of E-Cad-
herin can be retained or even increased [40–47].
Through invasion cancer cells migrate and metastasize. 
Invasion can be conceptualized as a single cell process or 
a collective invasion of multiple coherent cancer cells. In 
collective invasion, cells invade distant organs cohesively 
as a multicellular unit. Characteristically, in collective 
invasion, tumour cells maintain their cell–cell adhesion 
molecules, like E-Cadherin. Growing evidence suggests 
that collective invasion plays a major role in tumour pro-
gression [8, 48–54]. Our results support the hypothesis 
that E-Cadherin seems to be involved in collective cells 
behaviour that lead to invasion and metastasis.
In summary, our results contribute to the growing body 
of evidence that indicates both pro- and anti-tumorigenic 
properties of E-Cadherin. The different potential roles 
for E-Cadherin in the pathogenesis of tumour progress 
remain of ongoing interest. Based on our data, and in line 
with recent previous studies, we conclude, that continued 
expression of cell adhesion molecules do not necessar-
ily contribute to the suppression of tumour progression 
and metastases. Nevertheless, due to the limited sample 
size this observation warrants further validation in a larger 
patient cohort.
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